Craig-Hallum Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $16
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Craig-Hallum analyst Adam Vogel initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $16.
Craig-Hallum analyst Adam Vogel initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $16.
